Michael S Kaminer1, William P Coleman, Robert A Weiss, Deanne M Robinson, Jody Grossman. 1. *Skincare Physicians, Chestnut Hill, Massachusetts; †Coleman Cosmetic and Dermatologic Surgery Center, Metairie, Louisiana; ‡Maryland Laser Skin and Vein Institute, Hunt Valley, Maryland; §Connecticut Dermatology Group, Milford, Connecticut; ‖Ulthera, Inc., Mesa, Arizona.
Abstract
BACKGROUND: Cellulite is a common female cosmetic concern for which no single treatment option had been proven effective over the long term. A novel tissue stabilized-guided subsicion system (TS-GS system) has demonstrated significant reduction in the appearance of cellulite after treatment. OBJECTIVE: The objective of this extended follow-up period was to assess the effectiveness of TS-GS out to 3 years after initial treatment. PATIENTS AND METHODS: After completing an open-label, multicenter, pivotal study, 45 subjects were followed for an extended period of up to 3 years after receiving a single treatment using the TS-GS system. Treatment areas were photographed prior to the procedure and at multiple time points post-treatment throughout the 3 years. In this open-label study, subjects served as their own controls. Effectiveness was assessed based on blinded independent physician panel assessments of improvement from baseline using a cellulite severity scale. Subject aesthetic improvement and patient-reported satisfaction were also collected. RESULTS: The results of this trial supported Food and Drug Administration clearance of the device for the long-term reduction in the appearance of cellulite following TS-GS. CONCLUSION: These data further demonstrate the safety and efficacy of this treatment with no reduction in treatment benefits out to 3 years.
BACKGROUND: Cellulite is a common female cosmetic concern for which no single treatment option had been proven effective over the long term. A novel tissue stabilized-guided subsicion system (TS-GS system) has demonstrated significant reduction in the appearance of cellulite after treatment. OBJECTIVE: The objective of this extended follow-up period was to assess the effectiveness of TS-GS out to 3 years after initial treatment. PATIENTS AND METHODS: After completing an open-label, multicenter, pivotal study, 45 subjects were followed for an extended period of up to 3 years after receiving a single treatment using the TS-GS system. Treatment areas were photographed prior to the procedure and at multiple time points post-treatment throughout the 3 years. In this open-label study, subjects served as their own controls. Effectiveness was assessed based on blinded independent physician panel assessments of improvement from baseline using a cellulite severity scale. Subject aesthetic improvement and patient-reported satisfaction were also collected. RESULTS: The results of this trial supported Food and Drug Administration clearance of the device for the long-term reduction in the appearance of cellulite following TS-GS. CONCLUSION: These data further demonstrate the safety and efficacy of this treatment with no reduction in treatment benefits out to 3 years.
Authors: Sabrina Fabi; Tatjana Pavicic; André Braz; Jeremy B Green; Kyle Seo; Jani Aj van Loghem Journal: Clin Cosmet Investig Dermatol Date: 2017-10-30
Authors: Roberto Amore; Domenico Amuso; Vincenza Leonardi; Andrea Sbarbati; Giamaica Conti; Maria Albini; Francesco Leva; Ferdinando Terranova; Antonio Guida; Konstantinos Gkritzalas; Liya Gavashely; Roman Velichenko Journal: Plast Reconstr Surg Glob Open Date: 2018-05-18
Authors: Neil S Sadick; Mitchel P Goldman; Genzhou Liu; Neil H Shusterman; Michael P McLane; David Hurley; V Leroy Young Journal: Dermatol Surg Date: 2019-08 Impact factor: 3.398
Authors: Joely Kaufman-Janette; John H Joseph; Michael S Kaminer; James Clark; Sabrina G Fabi; Michael H Gold; Mitchel P Goldman; Bruce E Katz; Kappa Peddy; Joel Schlessinger; V Leroy Young; Matthew Davis; David Hurley; Genzhou Liu; Michael P McLane; Saji Vijayan; Lawrence S Bass Journal: Dermatol Surg Date: 2021-05-01 Impact factor: 2.914